EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bone Marrow Biopsy in the PET/CT Era: Its Role in Hodgkin and Common B-Cell Lymphomas: A Contemporary Narrative Review

Cezara Tudor, Andreea Stanciu, Tatiana Adam, Andreea Georgiana Stoica, Miruna Gherase-Cristian, Delia Maria Popescu, Dragos Emanuel Savin, Ariadna-Maria Mircescu, Teodora Sidonia Bajenaru, Raluca Mititelu

Cancers · 20.11.2026 · 18 (22) · 3712

DOI: 10.3390/cancers18223712 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 20.11.2026. Verfasst von Cezara Tudor und 9 weiteren Autor:innen. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bone marrow biopsy (BMB) provides histological information that complements whole-body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT). Its clinical value varies across lymphoma subtypes and extends beyond staging.

Methods

This narrative review synthesizes the literature identified through PubMed, Scopus and ScienceDirect searches, supplemented by purposively selected guidelines, foundational studies and citation-linked publications. Recent evidence was prioritized, with older studies retained where needed to explain changes in practice. The synthesis distinguishes diagnostic accuracy, stage migration and consequences for patient management.

Results

Routine staging BMB can generally be omitted in PET-staged Hodgkin lymphoma and in DLBCL without a management-changing question about discordant or alternative marrow pathology. Marrow assessment remains part of guideline-based evaluation in FL, MCL and nodal or splenic MZL, particularly when localized treatment, unexplained cytopenias or diagnostic classification makes the result consequential. Pooled PET/CT sensitivity for FL marrow involvement was 67% (95% confidence interval, 38–87%). In one MCL cohort, the PET/CT-negative predictive value was 27.8% at a composite marrow involvement prevalence of 78.4%, illustrating the importance of disease prevalence and reference standards. FDG avidity of extra-nodal MZL lesions does not establish reliable detection of marrow infiltration. Aspirate-based ancillary tests can clarify clonal or alternative pathology, while ctDNA, radiomics and PET/MRI remain complementary approaches.

Conclusions

Marrow sampling should answer a defined clinical question. Subtype-specific guidance, laboratory abnormalities and the likely consequences of additional tissue information provide the basis for deciding when biopsy is useful.

Zitieren

APA

Tudor, C., Stanciu, A., Adam, T., Stoica, A. G., Gherase-Cristian, M., Popescu, D. M., Savin, D. E., Mircescu, A., Bajenaru, T. S., & Mititelu, R. (2026). Bone Marrow Biopsy in the PET/CT Era: Its Role in Hodgkin and Common B-Cell Lymphomas: A Contemporary Narrative Review. Cancers, 18(22), 3712. https://doi.org/10.3390/cancers18223712

Vancouver

Tudor C, Stanciu A, Adam T, Stoica AG, Gherase-Cristian M, Popescu DM, et al. Bone Marrow Biopsy in the PET/CT Era: Its Role in Hodgkin and Common B-Cell Lymphomas: A Contemporary Narrative Review. Cancers. 2026;18(22):3712. doi:10.3390/cancers18223712

BibTeX
@article{Tudor2026,
  author = {Tudor, Cezara and Stanciu, Andreea and Adam, Tatiana and Stoica, Andreea Georgiana and Gherase-Cristian, Miruna and Popescu, Delia Maria and Savin, Dragos Emanuel and Mircescu, Ariadna-Maria and Bajenaru, Teodora Sidonia and Mititelu, Raluca},
  title = {Bone Marrow Biopsy in the PET/CT Era: Its Role in Hodgkin and Common B-Cell Lymphomas: A Contemporary Narrative Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {22},
  pages = {3712},
  doi = {10.3390/cancers18223712}
}
Kostenlos starten →